A 24-Week, Phase IIa, Randomized, Double-blind, Placebo-controlled Study of Ziritaxestat in Early Diffuse Cutaneous Systemic Sclerosis (NOVESA).

Dinesh Khanna,Christopher P Denton,Daniel E Furst,Maureen D Mayes,Marco Matucci-Cerinic,Vanessa Smith,Dick de Vries,Paul Ford,Yasmina Bauer,Matthew J Randall,Mitra Ebrahimpoor, Laszlo Kupcsik, Pieter-Jan Stiers, Liesbeth Deberdt, Niyati Prasad,Sharlene Lim, Philippe Pujuguet, Sohail Ahmed

Arthritis & rheumatology (Hoboken, N.J.)（2023）

引用 4|浏览32

暂无评分

摘要

Ziritaxestat resulted in significantly greater reductions in mRSS at Week 24 than placebo; no new safety signals emerged. Biomarker analysis suggests ziritaxestat may reduce fibrosis. Modulation of the autotaxin/LPA pathway could improve skin involvement in patients with dcSSc. A plain language summary is available in the Supplement.

查看译文

关键词

ziritaxestat,systemic sclerosis

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要